U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091864) titled 'Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma' on July 21.
Brief Summary: This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain tumor in adults, with an average survival time of approximately 15-18 months despite therapy. Studies have shown that having a higher-than-normal amount of glucose in the blood (hyperglycemia) during radiation therapy is associated with poorer survival outcomes in glioblastoma...